Reviewing Auris Medical Holding AG (EARS)’s and OncoCyte Corporation (NYSEAMERICAN:OCX)’s results

We are contrasting Auris Medical Holding AG (NASDAQ:EARS) and OncoCyte Corporation (NYSEAMERICAN:OCX) on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auris Medical Holding AG N/A 0.00 N/A -1.92 0.00
OncoCyte Corporation N/A 0.00 15.21M -0.44 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Auris Medical Holding AG and OncoCyte Corporation.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Auris Medical Holding AG 0.00% 630.2% -100.9%
OncoCyte Corporation 0.00% -219% -119.6%

Liquidity

Auris Medical Holding AG’s Current Ratio and Quick Ratio are 0.9 and 0.9 respectively. The Current Ratio and Quick Ratio of its competitor OncoCyte Corporation are 2.6 and 2.6 respectively. OncoCyte Corporation therefore has a better chance of paying off short and long-term obligations compared to Auris Medical Holding AG.

Institutional & Insider Ownership

Roughly 9% of Auris Medical Holding AG shares are held by institutional investors while 16.3% of OncoCyte Corporation are owned by institutional investors. 16.57% are Auris Medical Holding AG’s share held by insiders. On the other hand, insiders held about 1% of OncoCyte Corporation’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Auris Medical Holding AG 6.21% -10.45% -35.91% 35% -84.87% -17.11%
OncoCyte Corporation -4.9% -29.94% 102.45% 34.69% 8.2% 139.13%

For the past year Auris Medical Holding AG has -17.11% weaker performance while OncoCyte Corporation has 139.13% stronger performance.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.